MarginsXMarginsX
Home › Markets › Health Care › GOSS

Gossamer Bio Inc. (GOSS)

GOSS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$10.98
+0.09% on the day
Market cap
$67.2M
Micro cap
Revenue · 2025
$48.5M
-57.7% on 2024
Net income · 2025
-$170.4M
-351.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1728117/000172811726000017/0001728117-26-000017-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerGOSS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2019
SEC CIK0001728117
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$48.5M
Net income-$170.4M
Operating income-$170.7M
Net margin-351.5%
Operating margin-352.2%
Revenue growth-57.7%
Cash$37.7M
Total assets$172.2M
P/E (computed)Net income was not positive
P/S (computed)1.4×

Warning signs

Cash runway
3.9 months
$51.2M cash at September 30, 2026
Share count, 1 year
+111.4%
2025-10-31 to 2026-11-07 · +117.1% over 3 years
Going-concern doubt
Yes
10-Q filed November 10, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Accordingly, these conditions raise substantial doubt about the Company's ability to continue as a going concern."
10-Q 2026-11-10
Cash and burn$51.2M cash; operating cash flow -$39.0M a quarter.Report 2026-09-30
Shares outstanding6,116,390 (2026-11-07); 231,456,247 a year earlier; 225,409,314 three years earlier. 1y figure adjusted for split (1-for-80 overall); 3y figure adjusted for split (1-for-80 overall).Cover page 2026-11-07
Reverse splits, 3 years1; latest 1-for-80 on 2026-09-11Source 2026-09-11
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-01-28
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-04-09
AuditorErnst & Young LLP, San Diego, California, United StatesPCAOB Form AP 2026-04-01
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$38.4M-$48.1M-$29.6M$51.2M$37.1M$78.4M10-Q 2026-11-10
Q2 2026
2026-06-30
$9.2M$16.9M-$39.4M$41.1M$36.1M$53.3M10-Q 2026-08-13
Q1 2026
2026-03-31
$17.0M-$46.7M-$38.7M$41.0MNo debt tags$55.5M10-Q 2026-05-15
Q4 2025
2025-12-31
$13.8M-$47.2M-$48.3M$37.7M$0$48.5M10-K 2026-03-17
Q3 2025
2025-09-30
$13.3M-$48.2M-$36.2M$8.9MNo debt tags$44.1M10-Q 2026-11-10
Q2 2025
2025-06-30
$11.5M-$38.3M-$47.1M$26.3MNo debt tags$40.2M10-Q 2026-08-13
Q1 2025
2025-03-31
$9.9M-$36.6M-$39.7M$29.0MNo debt tags$124.6M10-Q 2026-05-15
Q4 2024
2024-12-31
$9.4M-$33.0M-$35.5M$46.1M$0$114.7M10-K 2026-03-17

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-11-16
Latest annual report10-K2026-03-17
Latest quarterly / interim10-Q2026-11-10
Latest current report8-K2026-11-10
Latest proxyDEF 14A2026-09-16

Source: SEC EDGAR submissions feed, 490 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+12.3%
1 month+12.4%
3 months-19.3%
Year to date-95.6%
1 year-94.5%
From 52-week high-96.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
TENXTenax Therapeutics Inc.$1.48-8.64%$67.4M
ZYBTZhengye Biotechnology Holding Limited$1.43-4.67%$67.8M
MNOVMedicinova Inc$1.34-3.94%$68.7M
CRBPCorbus Pharmaceuticals Holdings Inc.$3.38-0.44%$69.5M
COYACoya Therapeutics Inc.$3.00-4.15%$70.4M
VTVTvTv Therapeutics Inc.$17.69-10.16%$71.0M
ACRVAcrivon Therapeutics Inc.$1.46+0.69%$62.6M
MAIAMAIA Biotechnology Inc.$1.01+1.00%$62.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier